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that, in practical terms, the test was not
suitable in its present form for routine
cancer screening. However, the relatively
high percentage of positive tests in early
cancer indicate the possible role ofmonitoring
the patients' response to treatment, in
detecting the recurrence of tumour at an
early stage and in differential diagnosis.
Further studies are currently in hand to
investigate the possible role of the Makari
intradermal test in the monitoring ofresponse
to treatment and in the early detection of
recurrent tumour. The preliminary results
of these studies indicate that the surgical
removal of a tumour may lead to the conver-
sion of the Makari skin test from positive to
negative and during the follow-up period a
negative test may convert to positive on the
appearance of local or distant recurrence of
the tumour. It is important to stress that
these data are of a preliminary nature and
that further experience is required with more
cases and a considerably longer period of
follow-up. Nevertheless, the present data
strongly support the need for further studies
in relation to the monitoring oftreatment and
the detection of recurrent tumour.
THE VALUE OF HORMONE MEAS-
UREMENTS IN TUMOUR MANAGE-
MENT. K. D. BAGSHAWE. Department of
Medical Oncology, Charing Cross Hospital,
London
The practice of measuring hormones and
other substances produced by tumours, or by
specific organs in response to tumours, is
becoming a major occupation in the cancer
field. One of the problems is to match the
resources available to the problems which can
be defined and the distinction between
research and clinical routine operation re-
quires constant assessment. The range of
possible measurements is already very wide
and the number of patients to whom tests
are applicable is already large even though
most of the measurements do not yet relate
to the commonest malignancies.
The measurement of tumour products as
diagnostic aids is well established as a means
ofdistinguishing between neoplastic and non-
neoplastic causes for certain rare but " in-
teresting" syndromes. But some important
applications are slow to reach clinical prac-
tice, possibly because the conditions them-
selves are not regarded as "interesting" to
physicians.
Measurements may be applied to prob-
lems oftumour localization. Selective venous
sampling probably has a limited area of
application but it has a requirement for
precision in measurements which is not
readily sustained on a routine basis. Locali-
zation of tumours within the CNS can take
advantage of the blood-brain barrier and
although such methods have been available
for gonadotrophin producing tumours for the
past decade, their use has not been widespread
even though they are of substantial practical
value.
Screening operations based on tumour
products are valid for only a limited range of
tumours at the present time. Again, the
interval between developing a technology
appropriate to such a problem and putting it
into clinical operation may be very long. In
the case of uncommon tumours, screening
programmes are practicable only if carried
out on a regional or national basis.
The concept of monitoring the clinical
course of tumours with serial measurements
has been established for a limited range of
tumours and it is clear that it may sometimes
be necessary to follow more than a single
indicator substance. Different indicator
substances may provide different forms of
information and the form of information
provided by a given indicator substance may
be different for different tumours.
Nevertheless, some propositions currently
discussed in this field should perhaps be
examined critically. Do we really mean
" predictive " tests? Also, where we are
threatened by complexity we should perhaps
seek to avoid it at the outset and extract a
maximum of information from the simplest
measurements. " Multiparametric Analysis "
is not an end in itself and may be a passing
reflection of present inadequacies.
HORMONES AND THE PROSTATE.
K. GRIFFITHS. Tenovus Institute for Cancer
Research, Welsh National School ofMedicine,
Cardiff.
Regression of prostatic carcinoma in a
large proportion of patients treated by anti-
androgen therapy, either castration or oestro-
gen administration, clearly indicates the188 B.A.C.R. 15TH ANNUAL GENERAL MEETING
sensitivity of these tumour cells to hormonal
stimulation. This treatment results in the
decrease in plasma testosterone, and al-
though the effectiveness ofthe therapy might
suggest that this androgen or its prostatic
metabolites may have some aetiological role
in the development of cancer of the prostate,
thereisatpresentlittleevidence toincriminate
any hormonal imbalance. It is of interest,
however, that McNeal (1970, Proc. 3rd
Tenovus Workshop, p. 23) has recently
challenged thetraditionalview that carcinoma
of the prostate orginates from atrophic,
androgen deprived epithelium of the gland
in the elderly man. Instead, he suggests that
carcinoma arises from active glandular
epithelium, again directing attention to an
aetiological role of prolonged androgenic
stimulation.
It is obvious therefore that further studies
are required of the relationship between pro-
static disease and endocrine function. Investi-
gations from these laboratories have to date
failedtoshowany majorsignificantdifferences
inthelevelsofprolactin, LH,FSH,androstene-
dione, testosterone oroestradiol-17/3 inplasma
fromnormalmen and those with either benign
prostatic hyperplasia or carcinoma of the
gland. More detailed studies in which plasma
hormone levels in patients on oestrogen
therapy were carefully monitored indicated
differences in the endocrine response between
patients and suggested that such studies may
provide more relevant and interesting data.
For example, the prolactin levels in the
plasma were found to be markedly elevated in
certain patients after initiation of oestrogen
therapy. Many earlier studies have directed
attention to the possible relationship between
prolactin and the prostate, and it is also
known that hypophysectomy can still pro-
duce regression of prostatic carcinoma even
after orchidectomy and adrenalectomy
(Fergusson, 1972, in Endocrine Therapy in
Malignant Disease, p. 237).
The eventual lack of responsiveness to
oestrogen therapy in many patients, resulting
in progression of the disease, has been
considered due to secondary production of
androgen by the adrenal. A series of
Synacthen stimulation tests on patients
before and during diethylstilboestrol therapy
indicated an increased capacity of the
adrenal to produce testosterone during
treatment.
Little information exists on human
prostatic steroid receptor complexes. Such
steroid receptor studies in relation to hormone
action within the prostatic cell are particu-
larly valuable, and may eventually indicate
the mechanism by which oestrogens can
directly influence the metabolism of the
prostate.
ASSAY OF STEROID HORMONE RE-
CEPTOR IN CANCERS, METHODO-
LOGYAND PERSPECTIVES. R. K. WAG-
NER, A. HUGHES and P. W. JUNGBLUT.
Max-Planck Institute for Cell Biology,
Wilhemshaven, Germany.
The assay of steroid hormone receptors is
now widely used as an index of hormone
dependency of certain cancers, since it is
known that receptors are required for the
full course of hormonal action. A variety of
procedures have been employedfor evaluating
the spare (unused) receptor content of
tissues. They make use of the high affinities
of receptors for their respective steroids,
which allows the measurement of labelled
steroid receptor complexes, after separation
from excess of free steroid and dissociation of
unspecific complexes. Another requirement
for accurate receptor assay is the ability to
distinguish between steroid receptor com-
plexes and those formed with specific plasma
proteins, contaminating tissue extracts.
All requirements are met in a single step by
the very sensitive agar gel electrophoresis at
low temperature, which allows e.g. the
determination of oestrogen- and androgen
receptors in mammary and prostate cancer
in the presence of sex hormone binding
protein (Wagner, 1972). In assessing the
predictive value of quantitative receptor
assays in cancers, it has to be considered that
the concentration of spare receptor depends
not only on the uniformity of the tissue
specimen investigated but also on the
hormonal status of the patient. Hormone
action is always accompanied by receptor
depletion and replenishment. The latter is
due to de novo synthesis rather than to
recycling of used receptor. Continuous
hormone supply can thus result in low actual
concentrations of spare receptor, which
should not be mistaken as an indicator of
" marginal " hormone dependency.